New modifications to the scaffold of previously reported HBV capsid assembly effectors such as BAY 41-4109, HAP-12 and GLS4 were explored. The anti-HBV activity in the HepAD38 system, and cytotoxicity profiles of each of the new compounds has been assessed. Among them, five new iodo-and bromo-heteroarylpyrimidines analogs displayed anti-HBV activity in the low micromolar range.
already infected with HBV, combined with the fact that people are unaware of their infection, results in continued spread of the virus. To date, there are seven FDA approved inhibitors for HBV, 2,3 but none can cure this viral infection. Moreover, these agents lack an important characteristic necessary to confer a cure, which is the ability to eliminate HBV cccDNA from the nucleus of infected hepatocytes. 4 To address this unmet clinical need, several HBV Capsid Assembly Effectors (CAE), have been developed over the years ( Figure  1) . 5, 6, 7, 8 Among them, BAY 41-4109, which was studied in a phase I clinical trial, 9 was found to misdirect the HBV capsid assembly and interfere with the viral infection. 10 Recent studies have also shown that the combination of nucleoside analogs like adefovir (ADV) or tenofovir (TFV) with either one of these capsid effectors could lead to a synergistic antiviral effects. 11, 12 Novira recently completed a phase Ia clinical trial with a new capsid assembly effector (NVR 3-778, later acquired by Johnson & Johnson), and revealed that combinations with Entecavir (ETV) or pegIFN had additive and/or synergistic antiviral activity leading to high viral load suppression efficacy in infected humanized mouse models. 13 Despite their mechanism of action not being completely clear, capsid assembly effectors seem to represent a promising cohort of molecules with curative potential when combined with other HBV inhibitors such as nucleoside analogs. 14 In our continuing efforts to identify more effective small antiviral molecules and based on the potential of these CAE, we report herein the synthesis and evaluation of four new series of HAP analogs ( Figure 2 ): Series I is comprised of "flexible" HAP derivatives bearing an extra CH 2 linker between the main core and the halogenated phenyl ring. Compounds from series II & III are aromatic version of HAP bearing a methylene linker between the pyrimidine core and the phenyl ring. Unsaturated dihydropyrimidine can potentially be aromatized to their pyrimidine form by human liver microsomes and thus lose their potency. 15 We hypothesized that the addition of an extra methylene linker could compensate for the loss of stereochemistry in the original structure. Finally, series IV include 5-and 6modifications that retain hydrogen bond accepting characteristics of the morpholine or the ester groups presents on the HAP scaffold. Other, less common functionalities such as a phosphonate or imidazolium groups were also evaluated.
A Biginelli cyclocondensation between β-ketoacetate 2, pyridine-2-carboximidamide salt 4 and phenylacetaldehydes 3a-b in isopropanol under microwave irradiation generated the corresponding compounds 5a and 5b. 16 Bromination of dihydropyrimidine 5b using Nbromosuccinimide (NBS) in 1,2-dichloroethane led to the intermediate 6a, which was easily substituted with morpholine, N-methylpiperazine, methoxyethanol or thiobenzene to form compounds 7a-d. Oxidation of these dihydropyrimidines using 2,3-dichloro-5,6dicyano-1,4-benzoquinone (DDQ) easily led to the desired pyrimidines 8a-f (Scheme 1). It is noteworthy that the bromination of compound 5a could not be achieved under the halogenation conditions described above and therefore, we had to prepare targeted compound 13 through the chemistry described in Scheme 2. Methyl 4-morpholino-3acetoacetate 11, synthesized by reaction of methyl 4-chloroacetoacetate 9 with morpholine, was quickly purified and directly reacted with aldehyde 3a to yield dihydropyrimidine 12.
Final oxidation with DDQ gave compound 13.
Aromatic analogs of bicyclic derivative 1 were synthesized using the chemistry described in Scheme 3. Compounds 15a-c were prepared via a three-component Biginelli-type cyclocondensation under microwave irradiation involving dimedone 14, pyridine-3carboximidamide 4a-c and the corresponding aldehyde 3a-b. Interestingly, all our attempts to purify and isolate compounds 15a-c failed due to the instability of these dihydropyrimidines, which are spontaneously oxidized to their pyrimidine form. Therefore, compounds 15a-c were directly treated with DDQ in toluene to afford the corresponding pyrimidines 16a-c.
Compounds 21a-f, 6-modified analogs of lead compound HAP-12, were prepared according to the chemistry described in Scheme 4. The one pot, 2 step, condensation of 2-chloro-4fluorobenzaldehyde 17 with methylacetoacetate 2 and pyridine-2-carboximidamide hydrochloride 4 under microwave irradiation gave dihydropyrimidine 19 in 53% yield. Bromination of 19 followed by substitution with various nucleophiles led to the formation of compounds 21a-f.
Finally, various 5-modified HAP analogs were prepared according to chemical reactions described in Scheme 5. Compounds 23a-b were obtained as described above by condensation of diketoester 22 with aldehyde 17a-b and carboximidamide 4 under microwave irradiation. Bromination of compounds 23a-b followed by nucleophilic substitution of the brominated intermediates with morpholine led to 6-methylmorpholino-HAPs 24a-b. Dihydropyrimidine-5-carboxylic acids 25a-d, were then acquired after hydrogenolysis of the corresponding benzylic ester (25a and 25c), or by using boron trichloride (25b and 25d). Thioester 26d, ester 26e and N,N-dimethylsulfamoyl 26f were synthesized from 25c under peptidic coupling conditions (EDC DMAP, DMF). Halodecarboxylation of carboxylic acids 25a-d in presence of a source of halogen, oxone and sodium carbonate yielded halo-HAPs 26a-c and 26g-i after 20 min 17, 18 It is noteworthy, that a longer reaction time or use of an excess of oxone resulted in the aromatization of compounds 26a-c. Introduction of the amide group at the 6 position (compounds 28a-b) was achieved by first protection of the dihydropyrimidine 26a and 26h with a carboxybenzyl group and reaction with acetamide in presence of a catalytic amount of palladium tris(dibenzylideneacetone) (0) and Xantphos. 19 Subsequent Cbz-deprotection using either boron trichloride or a palladium catalyzed hydrogenolysis afforded compounds 28a-b. Interestingly, the Buchwald-Hartwig amination could not be achieved directly from 5-iododihydropyrimidines 26a and 26h and the choice of the correct protecting group was key. Indeed, introduction of protecting groups such as t-butoxylcarbonyl, tosyl or mesyl groups led to the dehalogenation and aromatization of the starting materials under palladium catalyzed amination conditions. The in vitro anti-HBV activity of thirty new heteroarylpyrimidines (HAP) derivatives were assessed at concentration ranging from 0.001 to 10 µM in HepAD38 cells using real-time-PCR, as previously described by Stuyver et al., 2002 . 20 All samples were tested in duplicate and the concentration of compound that inhibited HBV DNA replication by 50% (EC 50 ) was determined using the Chou and Talalay method as previously described. 20 All data were given relative to the untreated control. In addition, cytotoxicity was determined by using the CellTiter 96 non-radioactive cell proliferation colorimetric assay (Promega) in peripheral blood mononuclear (PBM) cells and in human T lymphoblast (CEM), African green monkey kidney (Vero), and human hepatocellular carcinoma (HepG2) cells. Toxicity levels were measured as the concentration of test compound that inhibited cell growth by 50% (CC 50 ). As expected HAP-12, GLS4 and 3TC inhibited HBV DNA replication with EC 50 values <1 µM and were used as positive control. However, it is noteworthy that compound 1, resynthesized in our laboratory, did not express any activity against HBV in the HepAD38 system (Table 1 ) even though it was reported in the literature, to be a submicromolar inhibitor of HBV replication. 13 None of the compounds with an extra methylene group between the dihydropyrimidine or pyridine core (Series I, II, III) displayed anti-HBV activity at concentrations up to 10 µM (Table 1) . Interestingly, in these series, compounds 7d, 8d-e, 13, 16b-c showed single digit micromolar cytotoxicity in CEM cells.
As described in Table 2 , replacement of the morpholine core of HAP-12 with a phosphonate moiety, an imidazolium salt or a sulfone group was counterproductive and lead to inactive compounds 21a-c and 21e-f. Introduction of an azido group (Compound 21d) , on the other hand, only lead to a moderate decrease of potency (EC 50 = 7.5 µM) compared to HAP-12.
In our last series of compounds (Table 3) , various modifications at the 6-position were explored. Unfortunately, replacement of the methyl or ethyl ester of HAP-12 or GLS-4 with a thioester (26c), a trifluoroethyl ester (26e), a N-(N,Ndimethylsulfamoyl)carboxamide (26f) or an acetamide (28a-b) was detrimental to the anti-HBV potency of these compounds and none of them showed activity at concentration up to 10 µM. Interestingly, introduction of an iodine or a bromine atom at this position lead to the discovery of compounds 26a-b and 26g-i which displayed EC 50 values between 4.0 and 5.7 µM. Chlorine, however, was not a suitable modification and 26c was found to be inactive at 10 µM.
In conclusion, we have synthesized and evaluated more than thirty CAE analogs of HAP-12 and GLS4. Among them, we discovered five new 5-halogeno-heteroarylpyrimidines analogs that displayed anti-HBV activity in the low micromolar range. Despite some toxicity observed in certain cell lines, further modifications are currently being investigated and will be subject of future publications. Table 2 HBV inhibition and cytotoxicity of compounds 21a-f. 
